Menu UF Health Home Menu
 

Taimour Langaee, MSPH, Ph.D.

Taimour Langaee

Research Associate Professor and Graduate Coordinator

Pharmacotherapy and Translational Research

OFFICE: HSC PG-29

EMAIL: langaee@cop.ufl.edu

PHONE: 352-273-6357

CV: Link to CV

 

EDUCATION

  • Ph.D., Microbiology and Immunology, Laval University, Ste-Foy, Quebec, Canada
  • M.S.P.H. in Public Health, Tehran University of Medical Sciences, Tehran, Iran
  • M.S. in Microbiology, Tehran University of Medical Sciences, Tehran, Iran
  • B.S. in Microbiology, University of Texas at Arlington

BIOGRAPHICAL SKETCH

Dr. Langaee is a Research Associate Professor in the Department of Pharmacotherapy and Translational Research at the University of Florida (UF) College of Pharmacy and Director of the UF Center for Pharmacogenomics Genotyping Core Laboratory. Before joining the UF faculty in 2002, he completed three years of post-doctoral fellowship in Immunology and Molecular Biology, and Microbiology and Molecular Genetics working on developing HIV vaccine at the College of Medicine University of Montreal and High Density DNA chips for Pseudomonas aeruginosa at the College of Medicine University of Florida.

Dr. Langaee’s research interests are focused on pharmacogenetics (genetic-based variability in drug response) in cardiovascular and auto-immune diseases and developing microarray-based technology methods to facilitate disease diagnosis, genotyping of patients and discovering disease-gene associations.

AFFILIATIONS

  • American Society of Human Genetics (ASHG)
  • American Society for the Advancement of Science (AAAS)
  • American Society for Microbiology (ASM)

RESEARCH INTERESTS

  • Langaee’s research interests are focused on pharmacogenomics (genetic-based variability in drug response) in cardiovascular disease; pharmacogenomics of anticoagulants (Warfarin); Pharmacogenetics of Dichloroacetate(DCA); Clinical, Genetics and Microbial Interactions in Inflammatory Bowel Disease (IBD); Microbial resistance to antibiotics.

PUBLICATIONS

Yuxin N. Gong Y, Langaee TY, Moss JI, Cooper-Dehoff RM, Pepine CJ, Johnson JA. DNA variations in Voltage-gated Calcium Channel Beta 2 Subunit (CACNB2) Gene and their association with adverse cardiovascular outcomes in the INternational VErapamil SR-trandolapril STudy-GENEtic Substudy (INVESTGENES). (Accepted for publication in Circulation Genetics).

Ying Zhang, Qiyu Bao, Luc A. Gagnon, Ann Huletsky, Antonio Oliver, Shouguang Jin* and Taimour Langaee*. ampG gene of Pseudomonas aeruginosa and its role in beta-lactamase expression. Antimicrob Agents Chemother. 2010 Nov;54(11):4772-9.

Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MT, Chen CH, Motsinger-Reif A, Sagreiya H, Liu N, Wu AH, Gage BF, Jorgensen A, Pirmohamed M, Shin JG, Suarez-Kurtz G, Kimmel SE, Johnson JA, Klein TE, Wagner MJ; International Warfarin Pharmacogenetics Consortium. Blood. 2010 May 6;115(18):3827-34. Epub 2010 Mar 4.

Larisa H. Cavallari, Taimour Y. Langaee, Kathryn M. Momary, Nancy L. Shapiro, Edith A. Nutescu, Marlos A.G. Viana, Shital R. Patel, Julie A. Johnson. Genetic and Clinical Predictors of Warfarin Dose Requirements in African Americans. Clin Pharmacol Ther. 2010 Apr;87(4):459-64. Epub 2010 Jan 13.

Julio D. Duarte, Maximilian T. Lobmeyer, Zhiying Wang, Arlene B. Chapman, John G. Gums, Taimour Y. Langaee, Eric Boerwinkle, Stephen T. Turner, and Julie A. Johnson. Lack of association between polymorphisms in STK39, a putative thiazide response gene, and blood pressure response to hydrochlorothiazide. Pharmacogenet Genomics. 2010 Aug;20(8):516-9.

Full Publication List via PubMed RSS feed